Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 3/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 7/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.37 |
| ▸ | CHUK | O15111 | 5/20 | 0.37 |
| ▸ | INSR | P06213 | 3/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633347 | 0.88 | CCNK (0.40) | CCNKCDK12AURKAAURKBCAMKK2 | |
| SCHEMBL26686212 | 0.88 | CCNK (0.40) | CCNKCDK12AURKAAURKBCAMKK2 | |
| SCHEMBL26686734 | 0.83 | CCNK (0.44) | CCNKCDK12AURKAAURKBCAMKK2 | |
| SCHEMBL26686550 | 0.79 | CCNK (0.46) | CCNKCDK12CAMKK2TBK1MAPK8 | |
| SCHEMBL30633292 | 0.79 | CCNK (0.46) | CCNKCDK12CAMKK2TBK1MAPK8 | |
| SCHEMBL26686058 | 0.79 | JAK2 (0.53) | CCNKCDK12AURKAAURKBCAMKK2 | |
| SCHEMBL26686172 | 0.76 | JAK2 (0.51) | CCNKCDK12AURKAAURKBCAMKK2 | |
| SCHEMBL26686752 | 0.75 | CCNK (0.52) | CCNKCDK12CAMKK2TBK1MAPK8 | |
| SCHEMBL31240468 | 0.75 | CCNK (0.52) | CCNKCDK12CAMKK2TBK1MAPK8 | |
| SCHEMBL31420556 | 0.74 | NEK1 (0.48) | CCNKCDK12AURKAAURKBTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | CCNK 222/4885CDK12 171/4885AURKA 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.